GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » 12-1 Month Momentum %

Swedish Orphan Biovitrum AB (OSTO:SOBI) 12-1 Month Momentum % : 7.01% (As of Apr. 28, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-28), Swedish Orphan Biovitrum AB's 12-1 Month Momentum % is 7.01%.

The industry rank for Swedish Orphan Biovitrum AB's 12-1 Month Momentum % or its related term are showing as below:

OSTO:SOBI's 12-1 Month Momentum % is ranked better than
60.97% of 1112 companies
in the Drug Manufacturers industry
Industry Median: -5.73 vs OSTO:SOBI: 7.01

Competitive Comparison of Swedish Orphan Biovitrum AB's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's 12-1 Month Momentum % falls into.



Swedish Orphan Biovitrum AB  (OSTO:SOBI) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Swedish Orphan Biovitrum AB  (OSTO:SOBI) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Swedish Orphan Biovitrum AB 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (OSTO:SOBI) Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (OSTO:SOBI) Headlines

No Headlines